*.- Exhibition 8-9 November 2017.
Austria Trend Eventhotel Pyramide,
Vienna .
*******************
Clinical Trials for SYL1001, a Novel Short Interfering RNA for the Treatment of Dry Eye Disease .
Sylentis has performed several Phase I and Phase II clinical trials to evaluate the safety and efficacy of SYL1001 eye drops on the treatment of dry eye disease. Phase II results showed excellent tolerability and significant improvement in the disease after 10 days of treatment compared to placebo. Additionally, dose response biodistribution studies demonstrated good correlation with clinical results.
Non-Clinical, Preclinical and Clinical Development
Thursday, 9 November 2017 11:45 - 12:15